tbuckley/cabot-search huggingface dataset:
AB0289 Clinical Value of the Antinuclear Antibodies in the Rheumatoid Arthritis: A Study of 170 Patients
Authors: M. Jguirim, L. Mani, A. Mhenni, S. Zrour, M. Younes, I. Béjia, M. Touzi, N. Bergaoui
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The diagnosis of rheumatoid arthritis (RA) notably that of early arthritis, rests on a cluster of clinical and biological arguments. Among biological test, three families of autoantibodies have been selected: anti-citrullinated peptide Antibodies (ACPA), rheumatoid factor (RF) and antinuclear Antibodies (ANA) <h3>Objectives</h3> The objective of this study is to determine the clinical value of antinuclear antibodies in rheumatoid arthritis <h3>Methods</h3> A total of 170 patients were included with the diagnosis of rheumatoid arthritis meeting ACR 1987 criteria, in a retrospective study, between 1997 and 2014. Clinical, biological, radiological characteristics and comorbidities were assessed for each patient. <h3>Results</h3> The average age was 48.8 years [16- 86]. The predominance was for woman with a sex ratio 8.4. The average disease duration was 4 years [1-36]. An initial assessment by the DAS 28 showed that 70% of patients had high activity and 30% had moderate disease activity. Joint deformities were reported in 36% of cases. Extra-articular manifestations were reported in 46.5% of patients. Radiological destruction was observed in 76% of cases. The most prevalent comorbidities in this population were anemia (37.6%), osteoporosis (21.2%), diabetis (16.5%) and hypertension (11.8%) and 4 cases of renal failure. All patients received corticosteroids and 89% received methotrexate. 70 patients were followed over a period of 60.8 months. Of these patients, 67% had low disease activity, 20% had a moderate disease activity and 13% were non-responders. We used a biotherapy in only four patients. Seronegative rheumatoid arthritis was found in 20% of cases. RF was positive in 72% of cases, ACPA were positives in 42% of cases. ANA was positive in 14.7% of cases, among these patients we found positive anti SSA +/- SSB in six cases, positive anti RNP in four cases and positive anti DNA in tow cases. The diagnosis of Sjögren9s syndrome associated with RA was retained in six cases. <h3>Conclusions</h3> The search for ANA is used for differential diagnosis with other auto immune diseases such as Sjögren9s syndrome, scleroderma and lupus erythematosus. But ANA can exist in 20%&gt;45% of RA patients usually at a low rate. <h3>References</h3> Dijkmans D, van Schaardenburg D, van der Horst-Bruinsma IE, Reesink HW, Vandenbroucke JP, Boers M.The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis. Ned Tijdschr Geneeskd. 2005;149:688-93. <h3>Disclosure of Interest</h3> None declared
Induction of Hemangio-Endotheliomas and Sarcomas in Mice with &lt;italic&gt;o&lt;/italic&gt;-Aminoazotoluene
Authors: Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article Induction of Hemangio-Endotheliomas and Sarcomas in Mice with o-Aminoazotoluene Get access Howard B. Andervont Howard B. Andervont biologist National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 4, February 1950, Pages 927–941, https://doi.org/10.1093/jnci/10.4.927 Published: 01 February 1950 Article history Received: 09 December 1949 Published: 01 February 1950
SAT0600 Pathological Change Caused by Biological Drugs in Rheumatoid Arthritis Synovial Tissue
Authors: A. Kubota, M. Sekiguchi, T. Namakumura, S. Ikata, T. Suguro
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Various reports was made for biological drug impacts on pathological findings in rheumatoid arthritis (RA) synovial tissue. However the impact of the biologics on the synovial tissure is not unclear. <h3>Objectives</h3> We examined biological drug impacts on RA synovial tissues based on pathological findings in them collected during surgeries for the same patient before and after biological drug usage. <h3>Methods</h3> Synovial tissues were collected from 17 RA joints before and after biological drug usage. Inflammatory change in synovial tissues collected during surgeries was assessed by Rooney score. We examined correlation between pathological findings in RA synovium and disease activity under biological drug usage. Disease activity was assessed by CDAI. Etanercept, Infliximab and Tocilizumab was used as biological drug for 10, 5 and 2 joints respectively. <h3>Results</h3> Rooney score between before and after biological drug usage improved from 27.4 to 12.8 showing significant difference. Significant improvement in Rooney score was observed in all items. In remission and low groups after biological drug usage, Rooney score significantly decreased in items of synovial lining cells, perivascular lymphocytic infiltration, lymph follicle and lymphocytic infiltration. Significant difference in Rooney score was not observed in moderate group between before and after biological drug usage. <h3>Conclusions</h3> With decrease observed in single layer formation in synovial lining cells, angiogenesis in sub-synovial tissue, perivascular lymphocytic infiltration and lymph follicle, improvement in inflammatory change in synovium was achieved. Pathological findings in sub-synovial tissue suggested to have reflected disease activity. <h3>Disclosure of Interest</h3> None declared
Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Using Pharmacokinetic Modeling: Initial Experience in Patients With Early Arthritis
Authors: Karen I. Maijer, Christiaan van der Leij, Maria J. H. de Hair, Sander W. Tas, Mario Maas, Daniëlle M. Gerlag, Paul P. Tak, Cristina Lavini
Journal: Arthritis & Rheumatology (2015)

Analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using pharmacokinetic modeling (PKM) provides quantitative measures that mirror microvessel integrity and can be used as an objective marker of the level of synovial inflammation. The aim of this study was to investigate the PKM parameters K(trans) , kep , and ve in a prospective cohort of disease-modifying antirheumatic drug (DMARD)-naive patients with early arthritis, and to validate the results by assessing their correlation with the number of synovial endothelial cells (ECs). Forty-seven patients with early arthritis (arthritis duration <1 year, DMARD naive; comprising 14 patients with rheumatoid arthritis, 22 with unclassified arthritis, 6 with spondyloarthritis [SpA], and 5 with other arthritides) were included. At baseline, DCE-MRI was performed on an inflamed knee joint of each patient. These images were used to calculate the K(trans) (volume transfer constant between the plasma and extracellular extravascular space [EES]), the kep (transfer constant between the EES and plasma), and the ve (fractional volume of the EES). Second, markers of disease activity were collected. Finally, vascularity was evaluated by immunohistochemical analysis of synovial tissue samples obtained from the inflamed knee joints, using antibodies to detect von Willebrand factor (vWF), a marker of ECs. The 3 PKM parameters differed significantly between diagnostic groups at baseline, with the highest K(trans) value being observed in patients with SpA (median 0.050/minute, interquartile range [IQR] 0.041- 0.069). Furthermore, the K(trans) , kep , and ve values correlated significantly with markers of disease activity. Finally, the PKM parameters K(trans) and kep , but not ve , correlated significantly with synovial expression of vWF (r = 0.647, P = 0.004 for K(trans) ; r = 0.614, P = 0.007 for kep ; r = 0.398, P = 0.102 for ve ). These results suggest that the K(trans) , kep , and ve can be used to detect synovial inflammation in patients with early arthritis, and these PKM parameters may be helpful in differential diagnosis. This approach may also be useful in translational research analyzing tissue microcirculation and angiogenesis.
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection
Authors: Carole J. Henry Dunand, Paul E. Leon, Min Huang, Angela Choi, Veronika Chromikova, Irvin Y. Ho, Gene S. Tan, John Cruz, Ariana Hirsh, Nai-Ying Zheng, Caitlin E. Mullarkey, Francis A. Ennis, Masanori Terajima, John J. Treanor, David J. Topham, Kanta Subbarao, Peter Palese, Florian Krammer, Patrick C. Wilson
Journal: Cell Host & Microbe (2016)
Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients
Authors: Vittorio Stefoni, Alessandro Broccoli, Beatrice Casadei, Enrico Derenzini, Letizia Gandolfi, Cinzia Pellegrini, Federica Quirini, Lisa Argnani, Pier Luigi Zinzani
Journal: Blood (2014)
Abstract 1408: Generation of 3D-microtissues suitable for drug screening with lentivirally GFP-labelled CD44+CD24- breast cancer cells enriched by irradiation
Authors: Ines Höfig, Michael Rosemann, Michaela Albrecht, Yashodhara Ingawale, Jens M. Kelm, Michael J. Atkinson, Christian Thirion, Natasa Anastasov
Journal: Cancer Research (2015)

Abstract A stem cell like subpopulation of human T47D and MDA-MB-361 breast cancer cells (CD44+CD24-) was enriched by irradiation (2 Gy) and isolated using magnetic activated cell sorting. As an additional stem cell model, primary murine mesenchymal stem cells (MSCs) were isolated from the bone marrow of C3HxBL mice. We confirmed the stemness phenotype by repopulating heterogeneous cancer cell lines from isolated CD44+CD24- cells or by inducing differentiation of MSCs to the osteocyte, adipocyte and chondrocyte lineage. For gene delivery in cancer research, lentiviral transduction protocols are widely used though low transduction efficiencies of especially primary cells force the use of high lentiviral titers. In search for an optimized transduction protocol we came across a poloxamer-based chemical adjuvant to increase lentiviral gene delivery in primary cells [Höfig et al, Journal of Gene Medicine, 2012 and Höfig et al, Biomaterials, 2014]. Next we aimed to expand these benefits to transduce cells with a stem cell phenotype. After lentiviral transduction of a GFP encoding lentivirus in the presence of the poloxamer-based chemical adjuvant we could detect highest numbers of GFP expressing cells. Neither the chemical adjuvant nor the transgenic GFP expression altered the stemness phenotype of those cells analysed by repopulation or differentiation assays and by detection of stem cell markers on mRNA level (CD133 and Sox2). To monitor the fate of GFP-expressing CD44+CD24- cells, we cultured them in 3D-microtissues in mix with unlabelled bulk cells and analysed the effect of irradiation on cell number and location of CD44+CD24- cells within the spheroid. In this study we present a method for induction and isolation of human breast cancer cells with a stem cell like phenotype and developed an improved lentiviral transduction method by a chemical adjuvant preserving the stemness character in human and murine cells. Efficient lentiviral transduction enabled the generation of 3D-microtissues with GFP-labeled CD44+CD24- cells that both can be studied in cancer research and shall have applications for drug screening. Citation Format: Ines Höfig, Michael Rosemann, Michaela Albrecht, Yashodhara Ingawale, Jens M. Kelm, Michael J. Atkinson, Christian Thirion, Natasa Anastasov. Generation of 3D-microtissues suitable for drug screening with lentivirally GFP-labelled CD44+CD24- breast cancer cells enriched by irradiation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1408. doi:10.1158/1538-7445.AM2015-1408
The Breast Cancer Challenge of 1991
Authors: Hilde Schulte
Journal: JNCI Journal of the National Cancer Institute (1991)

The Breast Cancer Challenge of 1991 Get access JNCI: Journal of the National Cancer Institute, Volume 83, Issue 13, 3 July 1991, Pages 914–915, https://doi.org/10.1093/jnci/83.13.914 Published: 03 July 1991
Second-line treatment with a combination of 5-fluorouracil, adriamycin, and mitomycin-C (FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer
Authors: S. Lee, S. Oh, B. Kim, H. Kwon, S. Kim, M. Rho, Y. Kim, M. Rho, H. Kim
Journal: Journal of Clinical Oncology (2008)

15606 Background: Gemcitabine based chemotherapy is regarded as the standard treatment for patients with pancreatic and biliary tract cancer. But a standard second-line chemotherapy regimen has yet to be defined after gemcitabine treatment. We performed to evaluate the efficacy and safety of the combination of 5-fluorouracil (5-FU), adriamycin and mitomycin-C (FAM) as second line treatment in patients with pancreatic and biliary tract cancer. Patients and Methods: Patients with advanced pancreatic or biliary tract cancer previously treated with gemcitabine based chemotherapy were included in the study. Chemotherapy was given as follows: 5-FU, 800 mg/m2 on days 1–5 over 10 hour; mitomycin-C, 8 mg/m2 on day 1; and doxorubicin, 30 mg/m2 on days 1 every 4 weeks. Result: A total of 31 patients received 95 cycles of chemotherapy. 15 patients had pancreatic cancer. 11 patients had cholangiocarcinoma. Gall bladder cancer was observed 5 patients. Four (12.9%) patients evidenced partial responses. Eight patients (25.8%) showed stable disease. The median time to progression and overall survival time were 2.3 (95% CI: 1.0–3.6) months and 6.7 (95% CI: 4.4–9.0) months, respectively. Major hematologic toxicities included grade 1–2 anemia (43.2%), thrombocytopenia (20%), neutropenia (15.7%), and grade 3–4 neutropenia (13.7%). The most frequently detected non-hematological toxicities were grade 2 and 3 nausea/vomiting (31.3%). One patient of hemolytic uremic syndrome was observed after 8 cycles of treatment. Conclusion: The FAM regimen appears a safe and feasible salvage therapy in advanced pancreatic and biliary tract cancer previously treated with gemcitabine based chemotherapy. No significant financial relationships to disclose.
AB0750 Is there Any Influence of Infliximab Immunogenicity on its' Efficacy in Ankilosing Spondylitis Patients?: Table 1.
Authors: O. Rumyantseva, A. Botchkova, S. Krasnenko, M. Cherkasova, E. Alexandrova, S. Erdes
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> It is deemed that production of neutralizing antibodies (ABs) is one of the key reasons for loss of infliximab (Inf) efficacy in prolonged ankylosing spondylitis (AS) therapy. <h3>Objectives</h3> To evaluate dynamic changes of Inf concentration and anti-Inf ABs level in the serum of AS patients, receiving continuous Inf therapy. <h3>Methods</h3> The study included 54 pts (37 males, 17 females) with verified AS diagnosis meeting NY criteria (1984y), high disease activity (BASDAI&gt;4), and regular long term Inf infusions (&gt;1 y, max 10 years). Pts9 monitoring included regular blood tests for quantification of anti-Inf ABs (ELISA with commercial kit Immunodiagnostik AG, Germany) and measuring of Inf concentration. <h3>Results</h3> Based on Inf efficacy pts were grouped in two arms: Group 1 - 26 (48%) pts with loss of Inf efficacy (exacerbations within 2 – 4 weeks after infusion), Group 2– 28 (52%) with expected response to Inf therapy. In Group 1 anti-Inf ABs were detected significantly more often (<i>p</i>&lt;0.05 Mann-Whitney test), and Inf concentration was lower (p&gt;0.05 Mann-Whitney test) (see Table). Inverse correlation between Inf concentrations and levels of anti-Inf ABs was found in both groups (Spearman correlation). <h3>Conclusions</h3> Loss of Inf efficacy may be associated with production of Inf-neutralizing antibodies. Inf serum concentration inversely correlates with levels of anti-Inf antibodies. <h3>Disclosure of Interest</h3> None declared
Bladder Cancer
Authors: Janet M. Torpy
Journal: JAMA (2005)

Bladder CancerU rine is formed by the kidney and stored in the bladder.The bladder expands and contracts depending on how much urine is stored inside.Cancer can develop in the bladder as it does in other bodily organs.Most bladder cancer arises in the cells that line the bladder.The February 16, 2005, issue of JAMA includes an article about bladder cancer.
Radiotherapy plus Chemotherapy in Muscle-Invasive Bladder Cancer
Authors: Paul Cathcart, Richard Sylvester, James Catto
Journal: New England Journal of Medicine (2012)

To the Editor: Results from the Bladder Cancer 2001 (BC2001) trial by James and colleagues (April 19 issue)1 suggest that synchronous administration of f luorouracil and mitomycin C with radiotherapy improved locoregional recurrencefree survival among patients with muscle-invasive bladder cancer. However, two essential points regarding patient demographic characteristics and outcomes were not reported. First, there were no data regarding the outcomes among patients with primary tumors that could not be completely resected. The completeness of surgical resection before definitive treatment could have a clinically significant impact on the outcome. Second, we wonder whether the combined methods of treatment reduced bladder capacity in a clinically significant way; this reduction could influence the quality of life in these patients. Shiu-Dong Chung, M.D.
Combined modality therapy for lung cancer.
Authors: R J Baglan
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.2.807 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9469380 Combined modality therapy for lung cancer. R J BaglanxR J BaglanSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.2.807 PDF "Combined modality therapy for lung cancer.." Journal of Clinical Oncology, 16(2), pp. 807–808© 1998 by American Society of Clinical Oncology
Case 43-1972
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Albert R. Martin, Eugene J. Mark
Journal: New England Journal of Medicine (1972)

Presentation of CaseA 41-year-old man was admitted to the hospital because of dysuria.He was born and raised in Honduras. He came to this country three years previously and thereafter began to experience infrequent, brief episodes of dysuria. Two and a half years before admission there was the insidious onset of swelling of the dorsum of the right hand and forearm; six months later small papules appeared over the hand and forearm. One year before entry a fissure developed on the palmar surface of the hand, followed after several months by a similar fissure near the wrist. X-ray films . . .
PTH-330 Detection and treatment of liver metastasis from colorectal cancer
Authors: R Jones, A Newton, E Lisseter, M Jha
Journal: Gut (2015)

<h3>Introduction</h3> As the principal site of distant spread, the detection and management of liver metastasis is crucial in patients with colorectal cancer. Untreated, the median survival is around 6–12 months. The aim of this study was to assess the way in which colorectal liver secondaries are detected and to assess the outcomes associated with their management. <h3>Method</h3> We set up and prospectively maintained a database detailing the clinical and radiological features of all patients with liver metastasis secondary to colorectal cancer in a high-volume unit. For the period 2008–2012, we reviewed the events leading to a diagnosis of liver metastasis, the initial treatment intent and median survival rates. <h3>Results</h3> During the study period, 1292 new cases of colorectal cancer were discussed in our multidisciplinary team meeting and of these, 216 had liver metastasis confirmed by computed tomography (CT) scanning. Liver metastasis was noted at the time of the initial diagnosis in 160 patients and metachronous lesions were detected in 56 patients. Metachronous metastases were detected after a median of 12 months (range 3–53). The length of the interval had no bearing on survival. The majority of metachronous liver metastases were detected with scheduled monitoring (41% by carcino-embryonic antigen and 39% on surveillance CT scan) but 16% presented symptomatically. From the time of initial diagnosis, the median survival for the synchronous and metachronous cases was 53 months and 57 months, respectively. 20% of the synchronous and 88% of the metachronous cases were treated with curative intent after the initial diagnosis of colorectal cancer. Of the 216 patients diagnosed with liver metastasis, 50 (23%) were referred to the local hepatobiliary unit for consideration of metastectomy. 11 patients were deemed unresectable and a further eight patients were either unfit or declined resection. Liver resection was undertaken in 9% of the synchronous and 30% of the metachronous cases. From the time of their initial diagnosis, the median survival for the 31 patients who underwent hepatic metastectomy was 53 months; survival was 59 months in the synchronous and 47 months in the metachronous groups. <h3>Conclusion</h3> Scheduled colorectal cancer surveillance serves to identify the majority of liver metastases, but history-taking and examination lead on to detection in a significant minority. With appropriate patient selection, resection of both synchronous and metachronous liver secondaries offers a significant survival benefit. <h3>Disclosure of interest</h3> None Declared.